Cryoprecipitated Anti-Hemophilic Factor (Cryoprecipitate or Cryo)

Cryoprecipitated Anti-Hemophilic Factor is produced from the plasma of whole blood collected from volunteer blood donors who were qualified in accordance with all current regulations and requirements, including screening with the Uniform Donor History Questionnaire developed by the AABB and accepted by the Food and Drug Administration for screening of donors of transfusible blood components.

All products have been screened with the standard panel of infectious disease tests used to screen blood products for transfusion acceptability.

Whole blood units are collected into a standard blood bag system used for collection of whole blood for transfusion and containing CPDA-1 anticoagulant. Plasma is separated by centrifugation into an attached bag without disrupting the closed system in which the whole blood was collected. The plasma is frozen at <-20°C, then allowed to thaw at 37°C. As the plasma thaws, a precipitate forms. Most of the plasma in the bag is transferred into another sterilely connected bag. A small amount of plasma remains with the precipitate, forming the desired product, which is refrozen.

Subjects may be selected from our database based on:

• Blood type
• Gender
• Ethnicity

Packaging and Shipment

Following production and in alignment with the intended use of the product and the customer’s requirements, cryoprecipitate can be packaged and shipped frozen on dry ice for overnight delivery.

Continuous temperature monitoring data tracking devices are available for use at the customer’s request.